Bendamustine: A review of pharmacology, clinical use and immunological effects

Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalic, Hrvoje, Aurer, Igor, Batinic, Drago, Visnjic, Dora, Smoljo, Tomislav, Babic, Antonija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100486/
https://www.ncbi.nlm.nih.gov/pubmed/35506458
http://dx.doi.org/10.3892/or.2022.8325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100486/
https://www.ncbi.nlm.nih.gov/pubmed/35506458
http://dx.doi.org/10.3892/or.2022.8325

Ejemplares similares